PDF(Pubmed)
Abstract：
OBJECTIVE: The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists\' perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS.
METHODS: The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400.
RESULTS: The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications.
CONCLUSIONS: AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability with the use of AOM400-TIS in patients with schizophrenia.
METHODS: The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400.
RESULTS: The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications.
CONCLUSIONS: AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability with the use of AOM400-TIS in patients with schizophrenia.
摘要：
目的：最近批准了阿立哌唑每月一次400mg（AOM400）的两次注射开始（TIS）起始方案，在坚持方面有潜在的好处。本文描述的SaTISfy研究分析了西班牙精神科医生对住院时间的看法，精神分裂症管理，以及AOM400-TIS的使用。
方法：作者描述了使用41个问题的调查收集的汇总数据的生态学研究。50名精神科医生被要求提供他们对精神分裂症患者和AOM400治疗的看法。
结果：精神科医生报告说，58.3％的精神分裂症患者缺乏治疗依从性是住院的主要原因。阿立哌唑,在任何配方中，是最常用的治疗选择，为5名患者中的2.5（0.9）的平均值（SD）开处方，而98%的精神科医生选择AOM400-TIS治疗未能坚持以前治疗的患者。精神分裂症患者,不管他们的待遇，与接受AOM400-TIS治疗的精神分裂症患者相比，平均住院时间为17.7（3.93）天，平均住院14.2（4.18）天，减少3.5（3.86）天。与西班牙精神科急性患者的全国平均住院时间（19.18d）相比，接受AOM400-TIS治疗的患者减少了5（4.18）天。接受调查的精神科医生报告说，AOM400-TIS提高了安全性和耐受性。大多数精神科医生对AOM400-TIS的管理和结果感到满意。大多数精神科医生（90％）还报告说，AOM400-TIS消耗的医疗保健资源较少，主要是由于住院天数和合并用药的减少。
结论：AOM400-TIS被认为对住院时间有积极影响，从而对卫生保健资源的使用有积极影响。人们对坚持有积极的看法，安全,精神分裂症患者使用AOM400-TIS的耐受性。
方法：作者描述了使用41个问题的调查收集的汇总数据的生态学研究。50名精神科医生被要求提供他们对精神分裂症患者和AOM400治疗的看法。
结果：精神科医生报告说，58.3％的精神分裂症患者缺乏治疗依从性是住院的主要原因。阿立哌唑,在任何配方中，是最常用的治疗选择，为5名患者中的2.5（0.9）的平均值（SD）开处方，而98%的精神科医生选择AOM400-TIS治疗未能坚持以前治疗的患者。精神分裂症患者,不管他们的待遇，与接受AOM400-TIS治疗的精神分裂症患者相比，平均住院时间为17.7（3.93）天，平均住院14.2（4.18）天，减少3.5（3.86）天。与西班牙精神科急性患者的全国平均住院时间（19.18d）相比，接受AOM400-TIS治疗的患者减少了5（4.18）天。接受调查的精神科医生报告说，AOM400-TIS提高了安全性和耐受性。大多数精神科医生对AOM400-TIS的管理和结果感到满意。大多数精神科医生（90％）还报告说，AOM400-TIS消耗的医疗保健资源较少，主要是由于住院天数和合并用药的减少。
结论：AOM400-TIS被认为对住院时间有积极影响，从而对卫生保健资源的使用有积极影响。人们对坚持有积极的看法，安全,精神分裂症患者使用AOM400-TIS的耐受性。
